![Victor SAVEVSKI | Chief Innovation Officer | Master of Engineering | Istituto Clinico Humanitas IRCCS | Humanitas | Innovation & A.I | Research profile Victor SAVEVSKI | Chief Innovation Officer | Master of Engineering | Istituto Clinico Humanitas IRCCS | Humanitas | Innovation & A.I | Research profile](https://i1.rgstatic.net/ii/profile.image/941196952211457-1601410248254_Q512/Victor-Savevski.jpg)
Victor SAVEVSKI | Chief Innovation Officer | Master of Engineering | Istituto Clinico Humanitas IRCCS | Humanitas | Innovation & A.I | Research profile
PBX1-directed stem cell transcriptional program drives tumor progression in myeloproliferative neoplasm
![Matteo ZAMPINI | PostDoc Position | Biosciences and Biotechnologies, PhD | Istituto Clinico Humanitas IRCCS | Humanitas | Department of Oncology and Hematology | Research profile Matteo ZAMPINI | PostDoc Position | Biosciences and Biotechnologies, PhD | Istituto Clinico Humanitas IRCCS | Humanitas | Department of Oncology and Hematology | Research profile](https://i1.rgstatic.net/ii/profile.image/368815096516608-1464943779081_Q512/Matteo-Zampini.jpg)
Matteo ZAMPINI | PostDoc Position | Biosciences and Biotechnologies, PhD | Istituto Clinico Humanitas IRCCS | Humanitas | Department of Oncology and Hematology | Research profile
LMCome - Un trattamento che risponda alle esigenze cliniche del singolo paziente. Questa è la raccomandazione principale del Dr. Matteo Giovanni Della Porta, Direttore della Leukemia Unit del Cancer Center presso l'IRCCS
![Sindromi mielodisplastiche, le evoluzioni della terapia e il ruolo della diagnostica molecolare - YouTube Sindromi mielodisplastiche, le evoluzioni della terapia e il ruolo della diagnostica molecolare - YouTube](https://i.ytimg.com/vi/i3cXl1Lusso/mqdefault.jpg)